A Review on Thrombolytic Therapy used in Myocardial Infarction (Streptokinase vs Tenecteplase)

摘要

The most severe form of Acute Coronary Syndrome is ST elevation myocardial infarction which requires immediate therapy. Thrombolytic agents are the medications that are used widely for the treatment of myocardial infarction. Now day’s different types of thrombolytic drugs recurrently available in market: alteplase, anisteplase, urokinase, streptokinase, tenecteplase. Thrombolytic therapy should be given with maintaining proper safety in order to minimize the risk of clinically important bleeding as well as enhance the chances of successfully thrombolysis of clot. Beside proper knowledge of contraindication, evolutionary factor and combination of drug is essential for successful thrombolytic therapy. And also should know which drug may produce more efficacy in thrombolytic therapy. Streptokinase may produce more bleeding complications and less resolution of st-segment when compared to tissue-plasminogen activators such as tenecteplase. The mortality rate is very high in acute myocardial infarction. So, this can be reduced by providing tissue plasminogen activator within the time.